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Abstract
Hemodynamics play an important role in cardiogenic shock assessment for prognosis estimation and for phenotyping
cardiogenic shock. This is best done by pulmonary artery catheters. In general, at the beginning of cardiogenic shock, patients
have vasoconstriction, which over time may lead to vasodilation. This is often triggered by percutaneous mechanical circulatory
support. This review will elucidate the hemodynamics and the factors that possibly lead to vasodilation in patients with
mechanical circulatory support.
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Background

Current Knowledge

At present, there is a dearth of published literature
concerning the hemodynamics of prolonged percutaneous
mechanical circulatory support (pMCS). However, the
pathophysiology of vasodilation in patients with acute
myocardial infarctions has been described in particular after
longer persistence of cardiogenic shock.1,2 A similar
pathophysiology is seen in patients with congestive heart
failure-related cardiogenic shock. Initially, reduced cardiac
output and stroke volume are noted, and the body is trying to
counteract the reduced blood pressure by vasoconstriction, at
least in the beginning. Over time, inflammation increases and
leads to a vasodilation state because of a pro-inflammatory
response which might even be triggered by pMCS.

Multiple options are currently available for MCS. Each
option differs regarding flow, pump speed, cannulation,
placement options, and ability to unload the right or left
ventricle.3 The Society for Cardiovascular Angiography and
Interventions (SCAI) recently updated and published its
definition of cardiogenic shock.4 The SCAI SHOCK II
definition advises the team to use MCS to reverse severe
cardiogenic shock when a patient reaches stages D or E. The
goal of MCS at those stages is to stabilize the patients and
revert them to the A or B classification.

Unfortunately, we do not know when vasodilation truly
occurs. We hypothesize it occurs earlier in patients that have
undergone resuscitation, received MCS, or have active
bleeding. We also know that patients with cardiogenic shock
can develop concomitant septic shock and vice versa. Thus, a
combination of cardiogenic and septic shock can affect
treatment and outcomes.

In addition, data from trials and registries have identified
the cardiac power index as one of the strongest hemodynamic
parameters to predict outcomes.5 It is calculated by
multiplying the cardiac index by the mean blood pressure and
a factor (i.e., 0.0022). Some randomized trials have shown that
MCS can improve the cardiac index and, thereby, the cardiac
power index.6 However, in an individual patient data metaanalysis, this could not be shown for MCS versus control.6
Importantly, reperfusion can stop ischemia. In general, it
is thought that MCS along with inotropes and vasopressors
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can increase inflammation, which leads to vasodilation.1,2 The
timing and variance of inflammation may differ based on the
type of device used. The answer remains unknown, and
comparative data are needed.
In the intensive care unit, patients on MCS develop
inflammation and vasodilation over time. This common
observation is supported by a recent review article from
Krychtiuk and colleagues.7 Once a patient enters the severe
cardiogenic shock stages of D and E, often the systemic
vascular resistance goes down. At the same time, the
inflammatory activation increases, and systemic inflammatory
response syndrome is observed. Of note, this summary of
cardiogenic shock progression remains a theory and needs
more data over time.
Jentzer and colleagues studied concomitant sepsis in
patients with cardiogenic shock.8 Since 2000, the incidence of
concomitant cardiogenic shock and sepsis has increased. The
incidence is higher in patients with non-ST-elevation
myocardial infarction (NSTEMI) than in those with STEMI.
Without question, sepsis leads to vasodilation; thus, this
parameter must be considered when treating cardiogenic
shock.
The search for fast, objective, biomarker-based scores for
cardiogenic shock prognosis continues. The CLIP-Score was
recently developed from trial data and combines measures of
renal function, tissue hypoxemia, inflammation, and heart
failure (cystatin C, lactate, interleukin-6, and N-terminal
[NT]-pro hormone Brain natriuretic peptide, respectively).9
This underlines the importance of inflammation in the
cardiogenic shock progress, as shown in this objective
prognosis score.
Among treatments with extracorporeal membrane
oxygenation (ECMO), the combination with Impella devices
(ECMELLA) for venting recently emerged. In theory, the
concomitant use results in better pressure-volume curves and
improved outcomes compared to ECMO alone, as shown in
propensity-matched studies.10 However, patients with
ECMELLA had more complications, including severe and
moderate bleeding and hemolysis, access-site-related
ischemia, and abdominal compartment syndrome.10
In terms of medical therapy, vasodilation is generally
treated with vasopressors in the ICU. Norepinephrine is likely
the strongest and best vasopressor we currently have; thus, it
is recommended for use in patients with Impella or ECMO
support who remain in hypotensive cardiogenic shock.1
Currently, there is a lack of randomized evidence in
cardiogenic shock. Only a few adequately powered trials have
provided relevant data. There is strong evidence for early
revascularization for an acute myocardial infarction, as it can
reduce mortality.3 Multivessel coronary artery disease is
present in roughly 80% of the patients with cardiogenic shock,
and the CULPRIT-SHOCK trial determined that culprit
lesion-only PCI is better than immediate-multivessel PCI.11
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Multiple trials have confirmed norepinephrine is better than
any other vasopressor.3 However, more research is needed;
thus, multiple large-scale randomized trials are underway.3
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